Coronary Artery Disease, Atherosclerosis, Stent Placement
Conditions
Keywords
Cardiovascular disease, peripheral vascular disease (PVD), Ischemia
Brief summary
The purpose of this study is to see if one month of dual antiplatelet therapy (DAPT) combined with the placement of the Synergy® Stent with IVUS (intravascular ultrasound) is safe for patients who are at high risk of bleeding (HBR).
Detailed description
DAPT or Dual Antiplatelet Therapy is a combination of two medications given after a percutaneous coronary intervention (PCI) with a drug eluting stent. DAPT is used to help make the platelets in your blood slick so they don't clump or stick together. If the platelets stick together and form a blood clot in the stent it is called a stent thrombosis and will cause an immediate heart attack or MI. The medications used for DAPT are low dose Aspirin (81mg) and one of three (3) antiplatelet medications: ticagrelor (Brilinta), clopidogrel (Plavix) or prasugrel (Effient) . The standard length of time to take DAPT after a stent placement is 6 months to 1 year. Dapt is associated with an increased risk of bleeding. Because you are considered to be at a high risk for bleeding due to one or a combination of reasons this study is trying to determine if a shorter use of DAPT in combination with the Synergy® stent and an imaging tool called IVUS used during your PCI procedure is safe and effective to reduce the potential for serious bleeding events and early stent thrombosis. The Synergy® stent was chosen because of its enhanced method of healing and reduced inflammation of the artery after placement. Because of this the Synergy stent may be a better choice for patients who are at high risk for bleeding and could benefit from a shortened period of DAPT. Intravascular ultrasound or IVUS provides a visual image of the inside of the coronary artery. It is used in patients undergoing PCI or stent placement for a few reasons; prior to placing the stent it is used to measure the artery's width to select the proper size diameter of a stent, also the length of the blockage to select the appropriate length of the stent and to visualize the amount of narrowing or blockage. After the stent is placed IVUS is used to make sure the stent itself is fully expanded and sits up against the wall of the artery. This is called apposition. If stents are not fully expanded and sit up against the wall of the artery early reblockage may occur. In short the IVUS aids in the ideal placement of the stent. By using the combination of the Synergy® Stent with the IVUS the expectation is to safely decrease the length of time you take DAPT from 6-12 months to 1 month. With the benefit of decreasing the risk of bleeding events.
Interventions
DAPT - one of three (3) antiplatelet medications: ticagrelor (Brilinta), clopidogrel (Plavix) or prasugrel (Effient) with Aspirin. Aspirin loading dose (LD) = 325 mg. Aspirin maintenance dose (MD) = 81 mg. P2Y12 Inhibitor Loading Dose (investigator preference): Clopidogrel 600 mg PO x 1 or 75 mg PO daily x 4; Prasugrel 60 mg PO x 1; Ticagrelor 180 mg PO x 1. P2Y12 Inhibitor Maintenance Dose (investigator preference): Clopidogrel 75 mg PO daily; Prasugrel 10 mg PO daily; Ticagrelor 90 mg PO BID.
DEVICEThe Synergy® stent
IVUS guided stent
Sponsors
Boston Scientific Corporation
HonorHealth Research Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
DAPT or Dual Antiplatelet Therapy is a combination of two medications given after a percutaneous coronary intervention (PCI) with a drug eluting stent. The medications used for DAPT are low dose Aspirin (81mg) and one of three (3) antiplatelet medications: ticagrelor (Brilinta), clopidogrel (Plavix) or prasugrel (Effient). Because the patients are considered to be at a high risk for bleeding due to one or a combination of reasons this study is trying to determine if a shorter use of DAPT in combination with the Synergy® stent and an imaging tool called IVUS used during your PCI procedure is safe and effective to reduce the potential for serious bleeding events and early stent thrombosis. The Synergy® stent was chosen because of its enhanced method of healing and reduced inflammation of the artery after placement. The Synergy stent may be a better choice for patients who are at high risk for bleeding and could benefit from a shortened period of DAPT.
Eligibility
Sex/Gender
ALL
Age
75 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subject is considered at high risk for bleeding, defined as meeting one or more of the following criteria at the time of enrollment: * Greater than or equal to 75 years of age and, in the opinion of the investigator, the risk of bleeding associated with \>1 months of DAPT outweighs the benefit, * need for chronic or lifelong anticoagulation therapy * history of major bleeding (severe/life threatening or moderate bleeding based on the GUSTO classification) within 12 months of the index procedure, * history of stroke (ischemic or hemorrhagic), * renal insufficiency (creatinine ≥2.0 mg/dl) or failure (dialysis dependent), * platelet count ≥20,000/μLto ≤100,000/μL (microliters) * In the opinion of investigator, patient is at significant risk of falling * Patient abuses drugs or alcohol * Hemoglobin ≤11.0 u/dl 2. Subject must be 18 years of age 3. Subject must be able to take study required dual antiplatelet therapy (1 month of P2Y12 inhibitor and aspirin, 13 months of antiplatelet monotherapy) 4. Subject is willing to comply with all protocol requirements, including agreement to stop taking P2Y12 inhibitor at the 1-month milestone if eligible per protocol 5. Subject (or legal guardian) understands the trial requirements and the treatment procedures and provides written informed consent before any trial-specific procedures are performed Angiographic Inclusion Criteria: 1. Subject must have had implantation of at least one Synergy Stent and the use of Boston Scientific IVUS for guided stent implantation 2. All implanted stents must be post dilated and must meet the following IVUS success criteria: * treated lesions in which the stent cross sectional area exceeds the distal reference cross sectional area * if the stent cross sectional area is less than the distal reference cross sectional area additional post-dilatation must be performed, followed by IVUS * above IVUS criteria must be met after the 2nd post dilatation NOTE: if the IVUS criteria is not met after the 2 post dilatation the patient is excluded 3. Stent procedure performed by an approved investigator 4. Vessel diameter ≥ 2.25 mm and ≤4.0 mm and lesion length ≤34mm 5. Pre-dilatation is up to the discretion of the investigator
Exclusion criteria
1. Subject with an indication for the index procedure of acute ST elevation MI (STEMI) 2. Subject with an indication for the index procedure of Non ST elevation MI (NSTEMI), based on the 3rd Universal MI definition 3. Subject with treatment with another coronary stent, other than SYNERGY Stent during the index procedure 4. Subject with a planned staged procedure \>7 days following the index procedure. (Note: Planned staged procedures are allowed if performed within 7 days of the index procedure and only when SYNERGY stents are used for both the index and staged procedure). Discontinuation of DAPT should occur 1 month after the last PCI procedure is completed. 5. A staged procedure cannot in a 3rd epicardial vessel if 2 epicardial vessels were treated during the index procedure 6. Subject has a known allergy to: contrast (that cannot be adequately pre-medicated), the SYNERGY Stent system or protocol-required concomitant medications (e.g., everolimus or structurally related compounds, polymer or individual components, all P2Y12 inhibitors and aspirin) 7. Subject previously treated at any time with intravascular brachytherapy 8. Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding 9. Subject is participating in an investigational drug or device clinical trial that has not reached its primary endpoint (Note: registry, observational, data collection studies are not exclusionary) 10. Subject intends to participate in an investigational drug or device clinical trial within 12 months following the index procedure (Note: registry, observational, data collection studies are not exclusionary) 11. Subject is judged inappropriate for discontinuation from P2Y12 inhibitor use at 1 month, due to another condition requiring chronic P2Y12 inhibitor use * if at the 30 day visit, the patient has had a peri-procedural NSTEMI with an enzyme elevation \>5% of the upper 99th percentile of either creatine kinase-myocardial band (CK-MB) or Troponin, the patient should not be taken off DAPT 12. Subject with planned surgery or procedure necessitating discontinuation of P2Y12 inhibitor within 1 month following index procedure 13. Subject is a woman who is pregnant or nursing 14. Subject with a current medical condition with a life expectancy of less than 12 months 15. Subject with implantation of a drug-eluting stent other than SYNERGY Stent within 11 months prior to index procedure 16. Have been previously consented for this trial and screen failed 17. Any other clinically significant comorbidities, which in the judgement of the investigator, could compromise compliance with the protocol, interfere with interpretation of the study results, or predispose the patient to safety risks. Angiographic
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Cardiac Death | 1 to 13 months | Rate of cardiac death from 1 to 13 months post-index procedure in the as treated (eligible for 30 day DAPT cessation) population. |
| Rate of Myocardial Infarction | 1 to 13 months | Rate of myocardial infarction (SCAI definition) from 1 to 13 months post-index procedure in the overall enrolled intent-to-treat patient population |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Ischemia-driven (ID) Target Vessel Revascularization, | 1 to 13 months | Angina Assessment |
| Number of Participants With Target Vessel Failure | 1 to 13 months | Angina Assessment |
| Number of Participants With Definite/Probable Stent Thrombosis (ST) Based on Academic Research Consortium (ARC) Definition | 1 to 13 months | Rate of Academic Research Consortium (ARC) definite/probable stent thrombosis (ST) involving SYNERGY Stent® from 1 to 13 months post-index procedure |
| Number of Participants With All-Cause MI (Myocardial Infarction) | 1 to 13 months | Angina Assessment |
| Number of Participants With All-Cause Death | 1 to 13 months | Angina Assessment |
| Number of Participants With Major Bleeding | 1 to 13 months | Rate of major bleeding (GUSTO severe/life threatening + moderate) |
Countries
United States
Participant flow
Pre-assignment details
An Interim Analysis was completed on December 10, 2021 (Attachment 3) after the 50th enrolled subject completed the 60 day follow up visit. The DSMC (16MAR2022) reviewed the Interim Analysis and recommended to end the study at interim analysis due to no glaring outcomes from the study. They did not see a need to continue, simply due to other similar studies have been completed for similar devices and the point that DAPT can safely be discontinued for High Risk Bleeding patients has been shown.
Participants by arm
| Arm | Count |
|---|---|
| PCI With 30 Day DAPT Therapy Single group of patients undergoing IVUS stent placement for PCI with 30 day DAPT therapy regimen. DAPT therapy consists of Aspirin (325 mg loading dose \[if applicable\] and 81 mg for maintenance dose) and P2Y12 Inhibitor (INFO ABOUT THE DRUGS)
Dual Antiplatelet (DAPT) Therapy: DAPT - one of three (3) antiplatelet medications: ticagrelor (Brilinta), clopidogrel (Plavix) or prasugrel (Effient) with Aspirin.
Aspirin loading dose (LD) = 325 mg. Aspirin maintenance dose (MD) = 81 mg.
P2Y12 Inhibitor Loading Dose (investigator preference):
Clopidogrel 600 mg PO x 1 or 75 mg PO daily x 4; Prasugrel 60 mg PO x 1; Ticagrelor 180 mg PO x 1.
P2Y12 Inhibitor Maintenance Dose (investigator preference):
Clopidogrel 75 mg PO daily; Prasugrel 10 mg PO daily; Ticagrelor 90 mg PO BID.
The Synergy® stent: IVUS guided stent | 50 |
| Total | 50 |
Baseline characteristics
| Characteristic | PCI With 30 Day DAPT Therapy |
|---|---|
| Age, Customized Greater than or equal to 75 years of age | 50 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants |
| Race (NIH/OMB) More than one race | 5 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants |
| Race (NIH/OMB) White | 40 Participants |
| Region of Enrollment United States | 50 Participants |
| Sex: Female, Male Female | 20 Participants |
| Sex: Female, Male Male | 30 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 4 / 50 |
| other Total, other adverse events | 44 / 50 |
| serious Total, serious adverse events | 31 / 50 |
Outcome results
Primary
Number of Participants With Cardiac Death
Rate of cardiac death from 1 to 13 months post-index procedure in the as treated (eligible for 30 day DAPT cessation) population.
Time frame: 1 to 13 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| PCI With 30 Day DAPT Therapy | Number of Participants With Cardiac Death | 3 Participants |
Primary
Rate of Myocardial Infarction
Rate of myocardial infarction (SCAI definition) from 1 to 13 months post-index procedure in the overall enrolled intent-to-treat patient population
Time frame: 1 to 13 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| PCI With 30 Day DAPT Therapy | Rate of Myocardial Infarction | 0 Participants |
Secondary
Number of Participants With All-Cause Death
Angina Assessment
Time frame: 1 to 13 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| PCI With 30 Day DAPT Therapy | Number of Participants With All-Cause Death | 4 Participants |
Secondary
Number of Participants With All-Cause MI (Myocardial Infarction)
Angina Assessment
Time frame: 1 to 13 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| PCI With 30 Day DAPT Therapy | Number of Participants With All-Cause MI (Myocardial Infarction) | 1 Participants |
Secondary
Number of Participants With Definite/Probable Stent Thrombosis (ST) Based on Academic Research Consortium (ARC) Definition
Rate of Academic Research Consortium (ARC) definite/probable stent thrombosis (ST) involving SYNERGY Stent® from 1 to 13 months post-index procedure
Time frame: 1 to 13 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| PCI With 30 Day DAPT Therapy | Number of Participants With Definite/Probable Stent Thrombosis (ST) Based on Academic Research Consortium (ARC) Definition | 0 Participants |
Secondary
Number of Participants With Ischemia-driven (ID) Target Vessel Revascularization,
Angina Assessment
Time frame: 1 to 13 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| PCI With 30 Day DAPT Therapy | Number of Participants With Ischemia-driven (ID) Target Vessel Revascularization, | 0 Participants |
Secondary
Number of Participants With Major Bleeding
Rate of major bleeding (GUSTO severe/life threatening + moderate)
Time frame: 1 to 13 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| PCI With 30 Day DAPT Therapy | Number of Participants With Major Bleeding | 4 Participants |
Secondary
Number of Participants With Target Vessel Failure
Angina Assessment
Time frame: 1 to 13 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| PCI With 30 Day DAPT Therapy | Number of Participants With Target Vessel Failure | 0 Participants |